Exelixis Business Operations Contracts & Agreements

Fifth Amendment dated August 24, 2023, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on November 1, 2023)

Fourth Amendment dated October 11, 2022, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 7, 2023)

Second Amendment dated May 7, 2019, to Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)

Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on May 10, 2022)

Third Amendment dated December 10, 2021, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 18, 2022)

First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on May 6, 2021)

Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on November 5, 2020)

Second Amendment dated May 7, 2020, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Myers Squibb... (Filed With SEC on August 6, 2020)

Amendment No. 3 dated November 22, 2019, to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on February 25, 2020)

Amendment No. 2 dated August 15, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Myers Squibb Company (Filed With SEC on October 30, 2019)

Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on July 31, 2019)

Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on July 31, 2019)

Amendment No. 1 dated March 8, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Meyers Squibb Company (Filed With SEC on May 1, 2019)

Amendment #3 dated May 29, 2018, to Cooperative Research and Development Agreement for Extramural-PHS Clinical Research by and between The U.S. Department of Health and Human... (Filed With SEC on February 22, 2019)

Ono Territorial Supplemental Agreement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Ono Pharmaceutical Co., Ltd. and... (Filed With SEC on November 1, 2018)

Supplement dated July 6, 2018 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb Company and Takeda... (Filed With SEC on November 1, 2018)

First Amendment dated July 6, 2018 to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Meyers Squibb... (Filed With SEC on November 1, 2018)

First Amendment dated March 22, 2018, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited (Filed With SEC on August 1, 2018)

First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 26, 2018)

Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on February 26, 2018)

Second Amendment dated September 14, 2017, to Collaboration and License Agreement by and between Exelixis, Inc. and Ipsen Pharma SAS (Filed With SEC on November 1, 2017)

Third Amendment to the Collaboration Agreement (Filed With SEC on August 2, 2017)

SUPPLEMENT TO THE CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on May 1, 2017)

CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on May 1, 2017)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 1, 2017)

First Amendment to the Collaboration Agreement (Filed With SEC on February 27, 2017)

COLLABORATION AGREEMENT (Filed With SEC on February 27, 2017)

FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on February 27, 2017)

Amendment #2 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial... (Filed With SEC on February 27, 2017)

Amendment #1 Cooperative Research and Development Agreement #11-1-00006 Clinical Development of Exelixis Inc.s Proprietary Cabozantinib (XL184), a MET and Vascular Endothelial... (Filed With SEC on February 27, 2017)

PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on February 27, 2017)

COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS 2017 Cash Compensation for Non-Employee Directors Board of DirectorsRetainer Fee $25,000 Additional Chair Retainer Fee $30,000... (Filed With SEC on February 27, 2017)

AMENDED AND RESTATED COLLABORATION AGREEMENT (Filed With SEC on August 3, 2016)

SUPPLY AGREEMENT (Filed With SEC on May 4, 2016)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 4, 2016)

Category

Industry

Companies

Contracts

Exelixis Business Operations Contracts & Agreements